A New York federal judge has dismissed murder and weapons charges against Luigi Mangione, the man accused of killing UnitedHealthcare's CEO. The ruling deals a significant setback to federal prosecutors and removes the possibility of a death penalty in the high-profile case.
President Donald Trump's nomination of Kevin Warsh to lead the Federal Reserve sets the stage for a potential pivot in U.S. monetary policy, placing a seasoned yet controversial figure with deep Wall Street ties at the helm.
Exclusive footage and soldier testimonies reveal a disturbing pattern within Russian ranks: wounded amputees, including former prisoners, are being ordered back into combat as casualties mount and manpower dwindles.
Denmark's government announced a bold legislative package aimed at expanding deportations and tightening immigration controls, setting the stage for a potential clash with the European Court of Human Rights.
The NBA's Minnesota Timberwolves have released a public statement calling for community solidarity following two separate fatal shootings involving federal immigration agents in Minneapolis, which have sparked protests and renewed debate over immigration enforcement.
Iran's foreign minister has unequivocally declared the nation's missile and defense capabilities non-negotiable, even as diplomatic efforts intensify to prevent a military escalation with the United States. The statement comes amid a complex backdrop of regional mediation and internal unrest.
Iran's foreign minister stated readiness for 'fair' negotiations with Washington but firmly ruled out discussing its defense capabilities, as regional powers intensify diplomacy to avert a military confrontation.
A combination of deep political polarization, economic pressures, and a growing brain drain is challenging Israel's viability as a secure and prosperous state, according to experts within and outside the country.
B. Riley initiates coverage of Adamas Trust (ADAM) with a Buy rating and a $9 price target, citing the REIT's strategic portfolio pivot towards higher-quality Agency RMBS as a key driver for potential revaluation.
GCL Global's fiscal first-half revenue nearly doubled after consolidating Ban Leong Technologies, yet the company reported a net loss as it absorbed acquisition costs. Management lowered full-year guidance, citing delays for two key game titles.
Germany's inflation rate ticked higher at the start of 2025, driven by rising food costs and persistent service price increases, even as energy prices provided some relief.
In a significant shift, Israeli military officials have privately told journalists that approximately 70,000 Palestinians have been killed in the Gaza war, a figure that largely corroborates the enclave's health ministry data, according to local media reports.
Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.
Dollar Tree shares have experienced notable turbulence, with a sharp weekly drop contrasting a strong yearly performance. This analysis delves into the conflicting valuation signals and the macroeconomic pressures shaping the discount retailer's investment narrative.
Electro Optic Systems (EOS), the Australian firm behind a landmark high-energy laser contract, is planning a strategic move of its headquarters and listing to Europe within the year, its CEO reveals, aiming to embed itself at the heart of the continent's urgent defence modernisation drive.
A fatal shark attack on a 13-year-old boy at a popular Brazilian beach has reignited concerns over coastal safety and led authorities to expand monitoring efforts along Pernambuco's coastline.
A campaign-trail proposal to temporarily cap credit card interest at 10% could offer significant savings for millions of borrowers, but experts warn of potential unintended consequences for credit access and long-term financial health.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
HSBC has cut its price target for AI infrastructure firm CoreWeave, warning that rising borrowing costs and significant future funding needs could strain the high-flying company's financial runway.
A detailed Discounted Cash Flow analysis suggests Eagle Eye Solutions Group (LON:EYE) shares are trading close to their estimated intrinsic value. We examine the assumptions behind the numbers and what investors should consider beyond the model.
